Joint Meeting of the
International Society for Cutaneous Lymphomas (ISCL)
and the
EORTC - Cutaneous Lymphoma Task Force
in cooperation with the
Japanese Association for Cutaneous Lymphomas
and the
Latin American Cutaneous Lymphoma Group
CUTANEOUS LYMPHOMAS: IMPROVING THE STANDARD OF CARE
Date/Time:
Sept. 29, 2007 (7.30 AM – 5:30 PM)
Venue:
Buenos Aires Sheraton Hotel & Convention Center (Congress Headquarters)
San Martin 1225, Buenos Aires
GOLDEN HORN room, 1st floor
Co-chairmen: R Knobler, N Pimpinelli
Scientific Program Committee (in alphabetical order):
R. Dummer, R. Knobler, E. Olsen, N. Pimpinelli, S. Whittaker.
SCIENTIFIC PROGRAM
Registration and Continental breakfast (7.30-8:30 AM)
Opening (8.30-8:45 AM)
E. Olsen, R. Knobler, K. Iwatsuki, J.A. Sanches Jr
Session 1 (8:45-10:00 AM)
Chairmen: P. Ortiz-Romero, M. Pittelkow, T Nagatani
ISCL/EORTC PROPOSAL FOR A REVISION TO THE STAGING AND CLASSIFICATION SYSTEM OF MF/SS
E. Olsen (8:45-9.05 AM)
DIAGNOSIS OF EARLY MF: APPLYING THE ISCL ALGORITHM
N. Pimpinelli (9.05-9.25 AM)
EORTC RECOMMENDATIONS FOR THE MANAGEMENT AND TREATMENT OF CTCL
R. Knobler (9:25-9:45 AM)
Discussion (9:45-10.00 AM)
Coffee Break and Poster Viewing (10:00-10.20 AM)
Session 2 ( 10:20-11:35)
Chairmen: A. Ranki, R. Dummer, J.A. Sanches Jr.
ISCL/EORTC PROPOSAL OF A STAGING SYSTEM FOR CUTANEOUS LYMPHOMAS OTHER THAN MF/SS
Y. Kim (10:20-10:40 AM)
ISCL/EORTC RECOMMENDATIONS FOR THE MANAGEMENT AND TREATMENT OF CBCL
R. Willemze (10:40-11:00 AM)
RARE SUBTYPES OF CUTANEOUS LYMPHOMA: DIAGNOSIS AND MANAGEMENT
E. Berti (11.00-11.20 AM)
Discussion (11:20-:11:35 AM)
Session 3 (11:35 AM – 12:15 pm)
Chairmen: T Estrach, R. Knobler, M.F. Demierre
SELECTED ABSTRACT PRESENTATIONS: PART I
CHARACTERIZATION OF PRIMARY AND SECONDARY CUTANEOUS LYMPHOMAS CONTROLLED AT PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE HOSPITAL DURING 22 YEARS.
M. Molgo (11:35-11:45 AM)
SUBCUTANEOUS PANNICULITIS-LIKE T-CELL LYMPHOMA: DEFINITION, CLASSIFICATION AND PROGNOSTIC FACTORS. AN EORTC CUTANEOUS LYMPHOMA GROUP STUDY OF 83 CASES.
R. Willemze (11:45-11:55 AM)
GENETIC CHARACTERIZATION OF PRIMARY CUTANEOUS T-CELL LYMPHOMAS BY ARRAY COMPARATIVE GENOMIC HYBRIDIZATION: PRELIMINARY RESULTS.
B. Espinet (11:55 AM- 12:05 PM)
CUTANEOUS T CELL LYMPHOMA TUMOUR CELLS ARE RESISTANT TO ACTIVATION INDUCED CELL DEATH BY UP-REGULATION OF c-FLIP
C-D. Klemke (12:05-12:15 PM)
Lunch and Poster Viewing (12:15-1:20 PM)
Session 4 (1:20-2:00 PM)
Chairmen: M. Bagot, H. Correa, J. Zic
SELECTED ABSTRACT PRESENTATIONS: PART II
AN IN-DEPTH ASSESSMENT OF THE IMPACT OF PRURITUS ON THE HEALTH –RELATED QUALITY OF LIFE OF PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA
M-F. Demierre (1:20-1:30 PM)
RECIPROCAL MODULATION OF CIRCULATING T REGULATORY SUBSETS INDUCED BY EXTRACORPOREAL PHOTOCHEMOTHERAPY IN CTCL AND CHRONIC GVHD.
P. Quaglino (1:30-1:40 PM)
CUTANEOUS T-CELL LYMPHOMA RESISTANCE TO PUVA/IFN-α TREATMENT IS RELATED TO TCR-SIGNALING AND NF-ĸB ACTIVATION
M. Wozniak (1:40-1:50 PM)
NOVEL IN SITU VACCINATION STRATEGY USING INTRATUMORAL INJECTION OF CPG-TYPE B, A TLR9 AGONIST, COMBINED WITH LOW-DOSE RADIATION IN MYCOSIS FUNGOIDES (MF) AND CUTANEOUS B-CELL LYMPHOMA (CBCL): AN INTERIM REPORT OF PHASE I/II STUDY
Y. Kim (1:50-2:00 PM)
Session 5: (2:00-3:00 PM)
Chairmen: M.G. Bernengo, K-H Cho, S. Whittaker
VIRUS-RELATED CUTANEOUS LYMPHOMAS: AN UPDATE
THE ASIAN EXPERIENCE
K. Iwatsuki (2.00-2.15 PM)
THE LATIN AMERICAN EXPERIENCE
F. Bravo (2.15-2.30 PM)
THE EUROPEAN EXPERIENCE
B. Dreno (2.30-2.45 PM)
DISCUSSION (2.45-3.00 PM)
Coffee Break: 3:00-3:15 PM and Poster Viewing
Session 6: (3:15-4:15 PM)
Chairmen: K Iwatsuki, E. Olsen, N. Pimpinelli
NEW/EMERGING TREATMENT MODALITIES
THE AMERICAN EXPERIENCE
M. Duvic (3:15-3:30 PM)
THE EUROPEAN EXPERIENCE
R. Dummer (3:30-3:45 PM)
THE JAPANESE EXPERIENCE
M Sugaya (3:45-4:00 PM)
DISCUSSION (4:00-4:15 PM)
Closing Remarks (4:15-4.30 PM)
R. Dummer, S. Whittaker
ISCL General Assembly (4:30-5:00 PM)
EORTC-CLTF Business Meeting (5:00-5:30 PM)
Special thanks to the following sponsors of the ISCL for 2007:
Platinum Sponsor
Merck & Co.
Gold Sponsors
Gloucester Pharmaceuticals
Therakos, Inc.
Silver Sponsor
GenMab
Transgene
4